In pursuing our goal of identifying new compounds that can selectively and specifically inhibit DNMTs we have built a team that combines in-house DNA methylation expertise with cutting edge molecular modeling and medicinal chemistry through collaboration.

Our in-house capabilities include:

  • Full cell and molecular biology analysis
  • Biochemical DNMT inhibitory assays
  • Measurement of DNMT inhibitory activity in cell lines
  • IT infrastructure for small molecule design and analysis